Comprehensive DNA Methylation Profiling in Breast Cancer as Biomarker for Prediction andPatient Stratification: A Concise Review

Global changes in DNA methylation correlate with altered gene expression and genomic instability in cancer. Early occurrence of gene-specific methylation alteration in breast cancer makes it a potential approach for early detection and prevention. As the trend of breast cancer prevalence in Iran is on the rise, early cancer detection and patient stratification seems to be crucial. Besides, new advances in next generation sequencing and highthroughput molecular profiling technology especially their application for methylation status analysis provided us valuable biomarkers for cancer prediction. Recent studies demonstrated distinct gene methylation profiles between breast cancer subtypes, with basal-like and luminal B tumors having the lowest and the highest methylation levels respectively. A total of 100 candidate genes were validated in literature of breast cancer and the deregulation of expression of 67 of these was associated with poor survival. Six genes (ACADL, ADAMTSL1, CAV1, NPY, PTGS2, and RUNX3) presented significant differential methylation among the 4 breast cancer subtypes and also between the ER+/ER- tumors. Also a panel of 13 hyper methylated genes as candidate biomarkers with high level of cancer prediction efficiency has been identified through hierarchical clustering analysis. Here is this review, we will discuss about 13 genes as a valuable biomarker for early detection of breast cancer included CST6, DBC1,EGFR, GREM1, GSTP1, IGFBP3, PDGFRB, PPM1E, SFRP1, SFRP2, SOX17, TNFRSF10D, and WRN. Further detail will be discus in the coming presentation.

کلیدواژه ها:

Breast Cancer ، Methylation ، Therapy ، Patient